Drugs in the Pipeline
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Drugs in the Pipeline, News
The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.
Drugs in the Pipeline
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
News
Currently, there are no approved treatments for COVID-19, however, several investigational therapies are in the works.
News
The Food and Drug Administration has cleared the initiation of a phase 3 trial evaluating INOpulse® inhaled nitric oxide (iNO) therapy (Bellerophon Therapeutics) in patients with coronavirus disease 2019 (COVID-19).
Drugs in the Pipeline
Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
News
A recently published case report describes the case of a 36-year-old male chronic heart failure patient who, "spontaneously expectorated an intact cast of the right bronchial tree," following an extreme bout of coughing.
News
The patient, who had a history significant for cerebral palsy, seizures, and chronic constipation, had presented complaining of 3 days of fever, nausea, vomiting, and anorexia.
Safety Alerts and Recalls
The use of e-cigarette products has been associated with several cases of severe pulmonary disease, according to the Centers for Disease Control and Prevention (CDC). In an official health advisory, the CDC stated that 215 possible cases have been reported across 25 states, with additional suspected cases still under investigation. One death has also been…
ATS 2020
Inhaled nitric oxide 45 mcg/kg of ideal body weight per hour was effective for improving physical activity in patients at risk for pulmonary hypertension associated with fibrotic interstitial lung disease.
